bazooka73 wrote: Pandora wrote: bazooka73 wrote: PeterG wrote:
Wangbang is not the manufacturer of 1067.
but they are for TFC-039
Did you read this or did you not read this:
This year, Empagliflozin (developed by Boehringer Ingelheim and Eli Lilly) failed to uphold patent protection in China, which created a generic environment for SGLT2 inhibitors. It was reported to us TFC-039 performed well in the clinical trials,
however, given the generic situation, it did not make good business sense for Wanbang to continue a lengthy and costly development”, said Dr. Howard Verrico, CEO of Sirona Biochem.
“While this is disappointing, we still see a path forward for TFC-039. We are working on several opportunities (both existing and new) for animal care globally. Our science team is also working on a new therapeutic indication, with potential strong advantages for TFC-039 compared to other compounds of the same class. This new indication has both unmet need and tremendous commercial value. The work done to date by Sirona and Wanbang will provide added value towards these opportunities, and we will also explore future involvement with Wanbang. Further dialogue will be occurring between Wanbang, and Sirona and any material news will be released accordingly.”
Are you assuming because of this last sentence that Wanbang is still manufacturing?
Did you read this?
"We are pleased to inform our shareholders that Sirona and Wanbang have signed a binding Letter of Intent (LOI) to collaborate on licencing efforts for Sirona’s SGLT2 inhibitor, TFC-039, as a treatment for diabetes in animal health. We have a long-standing relationship with Wanbang and are excited to combine our two companies’ expertise to license TFC-039 to a global animal healthcare company.
Previous efforts to license TFC-039 for this indication were delayed for reasons unrelated to the merit of the opportunity and interested parties are now able and willing to move forward. Discussions are rapidly progressing with several global companies to develop TFC-039 as a treatment for diabetes in companion animals. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication as opposed to the traditional method of daily insulin injections.
The combined scientific knowledge of Sirona and Wanbang will significantly increase the speed to commercialization of TFC-039. This includes extensive data, advanced manufacturing process development and the ability to commercially manufacture TFC-039. The new agreement was a desired step on the part of the interested partners to create the legal framework and to have certainty regarding production capacities and costs. Now that this has been finalized, the probability of a successful licensing agreement in the near future has been made much stronger.
This LOI is a modification of a previous agreement signed February 8th, 2021 which was mentioned in the CEO Update of 24 February 2021. The agreement will focus solely on applying TFC-039 to animal health.
Studies on a new indication for TFC-039 are also ongoing. Details of the new indication cannot be disclosed, but the opportunity as a valuable therapeutic exists and is an area of great need."
Are you assuming because of this CFO Update that Wanbang won't move on manufacturing TFC-039?